Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
XTL Biopharmaceuticals Sponsored ADR ( (XTLB) ) has provided an update.
On May 22, 2026, XTL Biopharmaceuticals disclosed that it received a Nasdaq Staff Determination letter dated May 18, 2026, stating the company is non-compliant with listing rules for failing to file its 2025 annual report on Form 20-F. Nasdaq indicated this filing delinquency is an additional basis for delisting, on top of XTL’s previously disclosed deficiencies relating to minimum stockholders’ equity and minimum bid price requirements.
The company has until May 26, 2026, to present its views in writing to the Nasdaq Hearings Panel and to request an extended stay of the suspension of its securities from the Nasdaq Capital Market. XTL said it intends to seek this stay, but cautioned there is no assurance the panel will grant continued listing, underscoring the heightened risk around its U.S. trading status for investors and other stakeholders.
Spark’s Take on XTLB Stock
According to Spark, TipRanks’ AI Analyst, XTLB is a Underperform.
XTL Biopharmaceuticals Ltd. shows considerable financial difficulties with persistent losses and weak cash flow. The technical analysis aligns with a bearish outlook, while valuation metrics highlight an unattractive investment at present. Although the stock has seen a recent price surge, the absence of earnings call details makes future performance uncertain.
To see Spark’s full report on XTLB stock, click here.
More about XTL Biopharmaceuticals Sponsored ADR
XTL Biopharmaceuticals Ltd. is an intellectual property-focused biopharmaceutical company that manages a portfolio including the hCDR1 asset for autoimmune conditions such as lupus (SLE) and Sjögren’s syndrome. The company seeks to expand its therapeutic offerings in high-value disease areas through strategic collaborations, sublicensing arrangements, and acquisitions, and its shares trade on Nasdaq and the Tel Aviv Stock Exchange.
Average Trading Volume: 1,885,405
Technical Sentiment Signal: Sell
Current Market Cap: $6.17M
See more data about XTLB stock on TipRanks’ Stock Analysis page.